Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
$3.44
+7.2%
$1.98
$1.47
$17.31
$78.21MN/A353,510 shs298,778 shs
ImmuCell Corporation stock logo
ICCC
ImmuCell
$6.76
-2.7%
$6.49
$3.34
$7.60
$62.81M0.3214,861 shs14,321 shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.24
-1.5%
$1.32
$1.12
$2.55
$61.77M0.422,975 shs103,163 shs
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
$4.22
-7.7%
$2.74
$1.08
$19.30
$14.47M0.9811.63 million shs712,789 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
+24.42%+34.87%+98.15%+31.02%-73.27%
ImmuCell Corporation stock logo
ICCC
ImmuCell
+1.76%+7.59%+4.51%+26.36%+67.47%
MediciNova, Inc. stock logo
MNOV
MediciNova
+1.57%+3.24%-3.85%-18.21%-4.58%
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
-11.26%-46.92%+311.71%+236.03%-32.95%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
2.6632 of 5 stars
3.50.00.00.01.91.71.3
ImmuCell Corporation stock logo
ICCC
ImmuCell
0.2762 of 5 stars
0.03.00.00.02.10.00.0
MediciNova, Inc. stock logo
MNOV
MediciNova
1.2145 of 5 stars
3.81.00.00.00.00.80.0
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
3.705 of 5 stars
3.55.00.00.02.60.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
3.00
Buy$17.80417.44% Upside
ImmuCell Corporation stock logo
ICCC
ImmuCell
0.00
N/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
3.50
Strong Buy$7.00464.52% Upside
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
3.00
Buy$20.00373.93% Upside

Current Analyst Ratings Breakdown

Latest SONN, MNOV, ARTV, and ICCC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/24/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
6/16/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy ➝ Strong-Buy$6.00 ➝ $5.00
6/11/2025
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$12.00
5/15/2025
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$23.00 ➝ $18.00
(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
$250K335.19N/AN/A$7.68 per share0.45
ImmuCell Corporation stock logo
ICCC
ImmuCell
$27.30M2.24$0.06 per share108.09$3.09 per share2.19
MediciNova, Inc. stock logo
MNOV
MediciNova
$1M60.82N/AN/A$1.07 per share1.16
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
$20K668.87N/AN/A($0.71) per share-5.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
-$65.37MN/A0.00N/AN/AN/A-75.95%-39.51%8/7/2025 (Estimated)
ImmuCell Corporation stock logo
ICCC
ImmuCell
-$2.16M-$0.07N/AN/A-1.00%-1.02%-0.61%8/12/2025 (Estimated)
MediciNova, Inc. stock logo
MNOV
MediciNova
-$11.04M-$0.23N/AN/AN/AN/A-20.77%-19.68%8/6/2025 (Estimated)
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
-$7.44MN/A0.00N/AN/A-777.92%-271.32%8/13/2025 (Estimated)

Latest SONN, MNOV, ARTV, and ICCC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025N/A
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.07N/AN/AN/AN/AN/A
8/13/2025Q3 2025
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
-$0.49N/AN/AN/AN/AN/A
8/7/2025Q2 2025
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
-$0.77N/AN/AN/AN/AN/A
5/14/2025Q1 2025
ImmuCell Corporation stock logo
ICCC
ImmuCell
N/A$0.16N/A$0.16N/A$8.07 million
5/13/2025Q1 2025
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.14-$0.06+$0.08-$0.06N/AN/A
5/13/2025Q2 2025
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
-$0.92-$0.89+$0.03-$0.89N/AN/A
5/8/2025Q1 2025
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
-$0.68-$0.83-$0.15-$0.83N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/AN/AN/AN/AN/A
ImmuCell Corporation stock logo
ICCC
ImmuCell
N/AN/AN/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
N/AN/AN/AN/AN/A
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/A
13.93
13.93
ImmuCell Corporation stock logo
ICCC
ImmuCell
0.30
4.12
2.21
MediciNova, Inc. stock logo
MNOV
MediciNova
N/A
17.66
17.66
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
N/A
1.03
1.03

Institutional Ownership

CompanyInstitutional Ownership
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/A
ImmuCell Corporation stock logo
ICCC
ImmuCell
13.47%
MediciNova, Inc. stock logo
MNOV
MediciNova
9.90%
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
9.45%

Insider Ownership

CompanyInsider Ownership
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
21.40%
ImmuCell Corporation stock logo
ICCC
ImmuCell
6.60%
MediciNova, Inc. stock logo
MNOV
MediciNova
13.60%
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
2.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
8124.36 million19.15 millionN/A
ImmuCell Corporation stock logo
ICCC
ImmuCell
709.04 million8.44 millionNot Optionable
MediciNova, Inc. stock logo
MNOV
MediciNova
1049.05 million42.38 millionOptionable
Sonnet BioTherapeutics Holdings, Inc. stock logo
SONN
Sonnet BioTherapeutics
103.17 million3.10 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Artiva Biotherapeutics stock logo

Artiva Biotherapeutics NASDAQ:ARTV

$3.44 +0.23 (+7.17%)
Closing price 04:00 PM Eastern
Extended Trading
$3.52 +0.08 (+2.18%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

ImmuCell stock logo

ImmuCell NASDAQ:ICCC

$6.76 -0.19 (-2.73%)
Closing price 04:00 PM Eastern
Extended Trading
$6.74 -0.02 (-0.30%)
As of 05:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

MediciNova stock logo

MediciNova NASDAQ:MNOV

$1.24 -0.02 (-1.55%)
Closing price 04:00 PM Eastern
Extended Trading
$1.24 0.00 (0.00%)
As of 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Sonnet BioTherapeutics stock logo

Sonnet BioTherapeutics NASDAQ:SONN

$4.22 -0.35 (-7.66%)
Closing price 04:00 PM Eastern
Extended Trading
$4.32 +0.10 (+2.25%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.